Warning for patients on Febuxostat (Uloric) to check with their GP after clinical trial shows elevated risk of death from the medication

The Tenerife Medical Association says that the Spanish Medicines and Sanitary Products Agency has issued an alert to patients taking Febuxostat (often sold under the brand name Uloric). Official advice today is that clinical trials now suggest the drug is not recommended for patients with gout, or cardiovascular or related conditions, for which it is most often prescribed, since it appears to incur “a significantly increased risk of death” from heart attack or stroke compared with other medication. Anyone on this medication is advised to see their GP to check if their prescription is appropriate or needs amending since this drug should only be taken where no alternative is possible for whatever reason.

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.